6

    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.08
    +0.05 (+4.85%)

    Market Cap: $3.62M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    25%(3/12)
    Avg Surprise
    -147.77%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.85
    Range$-0.85 - $-0.85
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.96-130.6%
    60d ago$-1.96-130.6%
    30d ago$-0.79+7.1%
    7d ago$-0.79+7.1%
    Current$-0.85
    Revenue Consensus
    $270000
    Range$270000 - $270000
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.72
    Range$-0.72 - $-0.72
    1 analysts
    Revenue Consensus
    $110000
    Range$110000 - $110000
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.72---
    Sep 26EST
    		-$-0.85---
    Jun 26
    		$-0.90$-0.74-21.62%Miss+79.2%
    Mar 26
    		$-1.21$-0.99-22.65%Miss+22.2%
    Dec 25
    		$-8.17$-2.00-308.50%Miss-278.2%
    Sep 25
    		$-2.53$-1.84-37.50%Miss+85.4%
    Jun 25
    		$-4.33$-4.96+12.70%Beat+94.9%
    Mar 25
    		$-1.56$-1.31-19.08%Miss+95.1%
    Dec 24
    		$-2.16$-0.18-1100.00%Miss-526.1%
    Sep 24
    		$-17.35$-17.40+0.29%Beat-109.4%
    Jun 24
    		$-84.60$-33.60-151.79%Miss-7590.9%
    Mar 24
    		$-31.54$-52.80+40.27%Beat-
    Dec 23
    		$-0.34$-0.14-146.43%Miss-
    Sep 23
    		$184.80$228.00-18.95%Miss-
    Jun 23
    		$-1.10$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.08EV/EBITDA22.23x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1092.00%
    ROE-332.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-1068.52x
    Current Ratio2.32xQuick Ratio1.78x
    Trading Statistics
    Beta2.54Avg Volume62.06K
    52-Week High$7.3652-Week Low$1.01

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.10
    SMA 20$1.13
    SMA 50$1.38
    SMA 200$2.27
    EMA 10$1.09
    EMA 20$1.15
    EMA 50$1.31
    EMA 200$2.51

    MACD

    Line: -0.08Signal: -0.09Hist: 0.01

    ADX

    ADX: 28.0+DI: 9.0-DI: 21.0

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down100.0
    PSAR$1.16

    Bollinger Bands

    Upper Band$1.23
    Lower Band$1.02
    %B Position1823%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    38.7

    Momentum Oscillators

    Stoch %K18.7
    Stoch %D22.9
    Williams %R-72.0
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-125.7
    MFI (14d)56.8

    Volatility Measures

    ATR (14d)$0.11(10.0%)
    StdDev (20d)0.05
    Hist Vol63.1%(High)

    Volume Flow

    VWAP$1.06
    OBV285.8M
    AD Line3.3B
    CMF (20d)-0.046

    Volume Metrics

    Avg Vol (20d)61.1K
    Vol Ratio0.7x
    VWMA (20d)$1.14

    Pivot Points

    R3$1.21
    R2$1.16
    R1$1.10
    Pivot Point$1.05
    S1$0.99
    S2$0.94
    S3$0.88

    Advanced Oscillators

    TSI-29.38
    Ultimate Osc47.5
    KST-213.91

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$207,898$162,092$409,110$528,562$307,871$256,283$302,588$148,111$124,972$105,674$118,273$51,188
    Cost of Revenue$151,100$85,715$120,682$537,690$50,051$73,272$118,077$111,687$89,564$65,437$146,257$71,196
    Gross Profit$56,798$76,377$586,327$-100,088$50,881$90,280$197,329$23,606$35,408$40,237$-20,576$-20,008
    Operating Expenses$2.33M$2.17M$2.11M$2.32M$1.86M$2.09M$807,127$2.16M$4.22M$2.82M$1.72M$1.65M
    R&D$598,653$281,464$638,873$809,777$231,912$370,813$613,955$940,063$3.10M$337,182$100,201$263,703
    SG&A$1.73M$1.89M$1.47M$1.51M$1.63M$1.72M$1.61M$1.22M$1.13M$1.08M$1.69M$1.31M
    Operating Income$-2,271,102$-2,094,961$-1,917,351$-2,325,525$-1,606,328$-1,910,938$-2,065,291$-2,118,692$-4,188,750$-1,342,448$-1,894,161$-1,521,762
    Interest Income$5,516$4,806$0$8,739$0$0$0$0$14,962$1.77M$0$5.70M
    Interest Expense$1,403$1,389$3,086$1,708$1,221$1,790$1,422$1,467$3,621$1,402$5,446$431,699
    Income Before Tax$-2,265,586$-2,090,155$-1,440,871$-2,316,786$-1,734,930$-1,877,301$-2,049,675$-2,160,248$-4,173,788$428,048$-2,046,156$4.17M
    Income Tax Expense$0$0$-1,813$250$0$0$-751$250$438$63$61$63
    Net Income$-2,265,586$-2,090,155$-1,439,058$-2,317,036$-1,734,930$-1,877,301$-2,479,394$-2,160,498$-4,174,226$858,455$-6,229,415$8.36M
    EBITDA$-2,181,945$-2,018,323$-1,370,100$-2,248,130$-1,669,914$-1,814,596$-1,988,188$-1,490,394$-1,406,492$576,949$-6,669,610$4.79M
    EBIT$-2,264,183$-2,088,766$-1,437,785$-2,315,078$-1,733,709$-1,875,511$-2,048,253$-2,158,781$-4,170,167$429,450$-6,997,524$4.58M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SXTP

    News

    60 DEGREES PHARMACEUTICALS, INC. SEC Filing (Aug 26, 2026)

    60 DEGREES PHARMACEUTICALS, INC. announced that its S-3 filing has been declared effective by the SEC on August 25, 2026, at 4:05 P.M. The filing was accepted by SEC EDGAR on August 26, 2026, at 12:15 AM. This notice indicates that the company's registration statement is now active.

    Stock Titan•8/26/26•
    Neutral

    Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

    This article summarizes analyst ratings for three healthcare stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC), and 60 Degrees Pharmaceuticals, Inc. (SXTP). OmniAb received a Strong Buy consensus with significant upside, while Bicycle Therapeutics and 60 Degrees Pharmaceuticals, Inc. both have a Moderate Buy consensus. Individual analysts from TD Cowen, Craig-Hallum, Morgan Stanley, and H.C. Wainwright provide specific ratings and price targets.

    The Globe and Mail•8/19/26•
    Neutral

    60 Degrees Pharmaceuticals (NASDAQ: SXTP) files to register 1.77M resale shares from warrant deal

    60 Degrees Pharmaceuticals (NASDAQ: SXTP) has filed an S-3 registration statement to register up to 1.77 million shares of common stock for resale by existing stockholders. These shares include those outstanding and those issuable from various warrants, all stemming from a private placement completed on July 30, 2026. The company will not receive any proceeds from these resales, only cash from warrant exercises, and clarified that the filing creates a future pathway for resale rather than documenting a completed sale.

    Stock Titan•8/14/26•
    Neutral

    ARAKODA maker reports about $2.4M Q2 loss with about $208K revenue

    60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported a net loss of approximately $2.40 million in Q2 2026, or $0.90 per share, despite a 106% increase in net product revenues to $208 thousand. The company, which develops medicines for vector-borne diseases and markets ARAKODA for malaria prevention, saw its operating expenses rise to $2.33 million. Three active clinical trials are underway for babesiosis, an emerging tick-borne disease.

    Stock Titan•8/14/26•
    Neutral

    60 Degrees Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SXTPW

    60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTPW) generated a total revenue of $627.40K USD last year. The "New Medicines" segment was the top-performing segment, contributing $1.01M USD, an increase from $607.57K USD in the previous year. The United States was the primary geographic contributor, accounting for $1.01M USD in revenue.

    TradingView•8/10/26•
    Neutral

    Frequently Asked Questions About SXTP

    Does SXTP pay dividends?
    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) does not currently pay a regular dividend.
    What is SXTP's market cap?
    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has a market capitalization of $3.62M with a current stock price of $1.08.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In